Base de dados : MEDLINE
Pesquisa : D04.210.500.668.651.693.175 [Categoria DeCS]
Referências encontradas : 1378 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 138 ir para página                         

  1 / 1378 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390539
[Au] Autor:Xu F; Liu C; Huang X
[Ad] Endereço:Department of Traditional Chinese Medicine, Xuanwu Hospital Capital Medical University, Beijing, China.
[Ti] Título:Oral contraceptives caused venous sinus thrombosis complicated with cerebral artery infarction and secondary epileptic seizures: A case report and literature review.
[So] Source:Medicine (Baltimore);96(51):e9383, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Venous sinus thrombosis is a special type of cerebrovascular disease. Its incidence is low and its symptoms are lack of specificity. And its early diagnosis and treatment are very difficult. PATIENT CONCERNS: This paper reported a rare case of a 43-year-old female who presented with cerebral venous thrombosis (CVT) complicated with cerebral artery infarction and secondary epileptic seizures due to oral contraceptives. DIAGNOSES: The final diagnosis was intracranial venous sinus thrombosis, acute cerebral infarction in the left parietal lobe, intracranial hypertension syndrome, and continuous epilepsy. INTERVENTIONS: The patient recovered well after active treatment. OUTCOMES: Three months after discharge, the muscle strength of the right limb of the patient was significantly increased, and no recurrence of neurological symptoms occurred. LESSONS: In conclusion, early diagnosis, correct evaluation, and standard treatment are still important challenges for CVT. Active treatment is recommended.
[Mh] Termos MeSH primário: Infarto Cerebral/etiologia
Anticoncepcionais Orais Sintéticos/efeitos adversos
Desogestrel/efeitos adversos
Epilepsia/etiologia
Trombose dos Seios Intracranianos/induzido quimicamente
[Mh] Termos MeSH secundário: Adulto
Infarto Cerebral/diagnóstico
Epilepsia/diagnóstico
Feminino
Seres Humanos
Trombose dos Seios Intracranianos/complicações
Trombose dos Seios Intracranianos/diagnóstico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Contraceptives, Oral, Synthetic); 81K9V7M3A3 (Desogestrel)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009383


  2 / 1378 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29310336
[Au] Autor:Park JU; Bae HS; Lee SM; Bae J; Park JW
[Ad] Endereço:Department of Plastic and Reconstructive Surgery.
[Ti] Título:Removal of a subdermal contraceptive implant (Implanon NXT) that migrated to the axilla by C-arm guidance: A case report and review of the literature.
[So] Source:Medicine (Baltimore);96(48):e8627, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: To report the distant migration of a subdermal contraceptive implant and to suggest that C arm-guided technique is one of the feasible options for removal of the device migrated to the axilla. PATIENT CONCERNS: A 41-year-old multipara with tingling sensation in the left axilla was referred for removal of an Implanon NXT which could not be palpated by physical examination or detected by ultrasound scanning. Finally, the device was detected by computed tomography and found migrating to the left axilla. DIAGNOSIS: Migration of Implanon NXT to the left axilla abutting the brachial plexus. INTERVENTIONS: The device was removed by C arm-guiding. OUTCOMES: The patient went home without any procedure-related complications. LESSONS: The incidence of distant migration of a subdermal implant is possible and should be checked up regularly. If the device cannot be palpated or detected by ultrasound at the original implanting site, this should be concerned. Since the single-rod subdermal implant is radiopaque, it can be detected by roentgenography. In this case the distant migration was detected in the axilla, therefore using C arm-guided technique is feasible for the removal of the migrating device. After reviewing the literature, totally 10 cases of distant migration were reported including 2 cases of migration which were advanced further to the pulmonary artery as an embolization.
[Mh] Termos MeSH primário: Anticoncepcionais Femininos
Remoção de Dispositivo
Implantes de Medicamento
Migração de Corpo Estranho/diagnóstico por imagem
Migração de Corpo Estranho/cirurgia
Radiografia Intervencionista
[Mh] Termos MeSH secundário: Adulto
Axila/diagnóstico por imagem
Axila/cirurgia
Desogestrel
Feminino
Seres Humanos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Contraceptive Agents, Female); 0 (Drug Implants); 304GTH6RNH (etonogestrel); 81K9V7M3A3 (Desogestrel)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180115
[Lr] Data última revisão:
180115
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008627


  3 / 1378 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28732067
[Au] Autor:Hasegawa S; Matsui T; Hane Y; Abe J; Hatahira H; Motooka Y; Sasaoka S; Fukuda A; Naganuma M; Hirade K; Takahashi Y; Kinosada Y; Nakamura M
[Ad] Endereço:Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
[Ti] Título:Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database.
[So] Source:PLoS One;12(7):e0182045, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Combined estrogen-progestin preparations (CEPs) are associated with thromboembolic (TE) side effects. The aim of this study was to evaluate the incidence of TE using the Japanese Adverse Drug Event Report (JADER) database. Adverse events recorded from April 2004 to November 2014 in the JADER database were obtained from the Pharmaceuticals and Medical Devices Agency (PMDA) website (www.pmda.go.jp). We calculated the reporting odds ratios (RORs) of suspected CEPs, analyzed the time-to-onset profile, and assessed the hazard type using Weibull shape parameter (WSP). Furthermore, we used the applied association rule mining technique to discover undetected relationships such as the possible risk factors. The total number of reported cases in the JADER contained was 338,224. The RORs (95% confidential interval, CI) of drospirenone combined with ethinyl estradiol (EE, Dro-EE), norethisterone with EE (Ne-EE), levonorgestrel with EE (Lev-EE), desogestrel with EE (Des-EE), and norgestrel with EE (Nor-EE) were 56.2 (44.3-71.4), 29.1 (23.5-35.9), 42.9 (32.3-57.0), 44.7 (32.7-61.1), and 38.6 (26.3-56.7), respectively. The medians (25%-75%) of the time-to-onset of Dro-EE, Ne-EE, Lev-EE, Des-EE, and Nor-EE were 150.0 (75.3-314.0), 128.0 (27.0-279.0), 204.0 (44.0-660.0), 142.0 (41.3-344.0), and 16.5 (8.8-32.0) days, respectively. The 95% CIs of the WSP-ß for Ne-EE, Lev-EE, and Nor-EE were lower and excluded 1. Association rule mining indicated that patients with anemia had a potential risk of developing a TE when using CEPs. Our results suggest that it is important to monitor patients administered CEP for TE. Careful observation is recommended, especially for those using Nor-EE, and this information may be useful for efficient therapeutic planning.
[Mh] Termos MeSH primário: Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/genética
Estrogênios/administração & dosagem
Estrogênios/efeitos adversos
Progestinas/administração & dosagem
Progestinas/efeitos adversos
Tromboembolia/induzido quimicamente
[Mh] Termos MeSH secundário: Adolescente
Adulto
Sistemas de Notificação de Reações Adversas a Medicamentos
Androstenos/administração & dosagem
Androstenos/efeitos adversos
Criança
Anticoncepcionais Orais Combinados/administração & dosagem
Anticoncepcionais Orais Combinados/efeitos adversos
Bases de Dados Factuais
Desogestrel/administração & dosagem
Desogestrel/efeitos adversos
Etinilestradiol/administração & dosagem
Etinilestradiol/efeitos adversos
Feminino
Seres Humanos
Japão
Levanogestrel/administração & dosagem
Levanogestrel/efeitos adversos
Masculino
Meia-Idade
Noretindrona/administração & dosagem
Noretindrona/efeitos adversos
Norgestrel/administração & dosagem
Norgestrel/efeitos adversos
Razão de Chances
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androstenes); 0 (Contraceptives, Oral, Combined); 0 (Estrogens); 0 (Progestins); 3J8Q1747Z2 (Norgestrel); 423D2T571U (Ethinyl Estradiol); 5W7SIA7YZW (Levonorgestrel); 81K9V7M3A3 (Desogestrel); N295J34A25 (drospirenone); T18F433X4S (Norethindrone)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170722
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0182045


  4 / 1378 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28599740
[Au] Autor:Dole DM; Martin J
[Ti] Título:What Nurses Need to Know About Immediate Postpartum Initiation of Long-Acting Reversible Contraception.
[So] Source:Nurs Womens Health;21(3):186-195, 2017 Jun - Jul.
[Is] ISSN:1751-486X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Initiation of long-acting reversible contraception (LARC) in the immediate postpartum period is becoming more common, resulting in increased requests for early removal, primarily because of unpredictable bleeding patterns. Competing interests of healthful spacing of pregnancies, impact on breastfeeding, risks associated with pregnancy versus contraceptive method, potential adverse effects of LARC, and timing of informed consent make immediate postpartum initiation of LARC an important issue. Nearly 40% of women do not attend a postpartum visit at all, resulting in decreased initiation of contraception and increased risk of unplanned pregnancy. Nurses caring for women during the peripartum period can help women make informed decisions and can provide anticipatory guidance regarding this method of contraception. Evidence-based postpartum education and support can result in women's increased continuation of and satisfaction with LARC.
[Mh] Termos MeSH primário: Anticoncepção/métodos
Mães/psicologia
Cuidado Pós-Natal/métodos
Fatores de Tempo
[Mh] Termos MeSH secundário: Adulto
Aleitamento Materno
Anticoncepção/normas
Contraindicações
Desogestrel/farmacologia
Desogestrel/uso terapêutico
Feminino
Seres Humanos
Dispositivos Intrauterinos de Cobre/normas
Educação de Pacientes como Assunto/normas
Segurança do Paciente/normas
Gravidez
Gravidez não Planejada/efeitos dos fármacos
Progestinas/farmacologia
Progestinas/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Progestins); 304GTH6RNH (etonogestrel); 81K9V7M3A3 (Desogestrel)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:170611
[St] Status:MEDLINE


  5 / 1378 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28594758
[Au] Autor:Carmo LSMP; Braga GC; Ferriani RA; Quintana SM; Vieira CS
[Ad] Endereço:Department of Gynecology and Obstetrics, Medical School of Ribeirao Preto, University of São Paulo, São Paulo, Brazil.
[Ti] Título:Timing of Etonogestrel-Releasing Implants and Growth of Breastfed Infants: A Randomized Controlled Trial.
[So] Source:Obstet Gynecol;130(1):100-107, 2017 Jul.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the growth of breastfed infants whose mothers had inserted an etonogestrel-releasing implant in the immediate postpartum period. METHODS: An open, randomized controlled, and parallel trial of postpartum women who were block-randomized to early (up to 48 hours postpartum before discharge) or conventional (at 6 weeks postpartum) insertion of an etonogestrel implant. The primary outcome was average infant weight at 12 months (360 days) and a difference of equal to or greater than 10% between groups was considered clinically significant. The secondary outcomes were infant's height and head and arm circumferences. These variables were measured at baseline and at 14, 40, 90, 180, 270, and 360 days postpartum. The mixed-effects linear regression model was used to evaluate the outcomes with a power of 80% and a significance level of 1% for the primary outcome and 0.3% for secondary outcomes as a result of correction for multiple hypothesis testing. RESULTS: From June to August 2015, a total of 100 women were randomized: 50 to early and 50 to conventional postpartum etonogestrel insertion. Sociodemographic characteristics were similar between the groups, except for educational attainment. The conventional insertion group included a higher proportion of women with 8 or more years of formal education than the early insertion group (88% [44/50] compared with 70% [35/50], P=.02). There was no difference in infant weight at 360 days between the groups (early [mean±standard deviation] 10.1±1.2 kg compared with conventional 9.8±1.3 kg, mean difference estimate 0.3 kg, 95% confidence interval 0-0.7 kg). Growth curves, height, and head and arm circumferences did not differ between the groups. CONCLUSION: There is no difference in growth at 12 months among breastfed infants whose mothers underwent early compared with conventional postpartum insertion of the etonogestrel implant. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02469454.
[Mh] Termos MeSH primário: Aleitamento Materno
Anticoncepcionais Femininos/administração & dosagem
Desogestrel/administração & dosagem
Implantes de Medicamento
Lactação/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adulto
Brasil
Anticoncepcionais Femininos/efeitos adversos
Desogestrel/efeitos adversos
Esquema de Medicação
Feminino
Seres Humanos
Recém-Nascido
Período Pós-Parto
Gravidez
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Contraceptive Agents, Female); 0 (Drug Implants); 304GTH6RNH (etonogestrel); 81K9V7M3A3 (Desogestrel)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170724
[Lr] Data última revisão:
170724
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170609
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002092


  6 / 1378 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28388997
[Au] Autor:Hopkins B
[Ti] Título:Barriers to Health Care Providers' Provision of Long-Acting Reversible Contraception to Adolescent and Nulliparous Young Women.
[So] Source:Nurs Womens Health;21(2):122-128, 2017 Apr - May.
[Is] ISSN:1751-486X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Despite recommendations for long-acting reversible contraception (LARC) as a first-line contraceptive method for adolescents and young women, its use in the United States remains low. This integrative review highlights previously unidentified barriers to health care providers' provision of LARC to adolescent and nulliparous young women. Four themes emerged: Appropriateness of Candidates and Contraceptive Safety, Provider Training and Work Setting, Appropriate Resources, and Opportunity. Raising awareness of barriers to LARC use may galvanize providers to find solutions. Nurses and other clinicians can remain aware of new contraceptive options and guidelines to reduce the risk of unintended pregnancy among adolescents.
[Mh] Termos MeSH primário: Anticoncepção/métodos
Pessoal de Saúde
Acesso aos Serviços de Saúde/normas
[Mh] Termos MeSH secundário: Adolescente
Anticoncepcionais Femininos/administração & dosagem
Desogestrel/administração & dosagem
Desogestrel/uso terapêutico
Feminino
Seres Humanos
Dispositivos Intrauterinos
Gravidez
Gravidez na Adolescência/prevenção & controle
Gravidez não Planejada
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Contraceptive Agents, Female); 304GTH6RNH (etonogestrel); 81K9V7M3A3 (Desogestrel)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170724
[Lr] Data última revisão:
170724
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:170409
[St] Status:MEDLINE


  7 / 1378 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28287679
[Au] Autor:Fernandez S
[Ti] Título:Long-Acting Reversible Contraception: A Primer for the Primary Care Pediatrician.
[So] Source:Pediatr Ann;46(3):e79-e82, 2017 Mar 01.
[Is] ISSN:1938-2359
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Long-acting reversible contraception (LARC) is the most effective method of preventing pregnancy in young women and adolescents. The two types of LARC methods are the intrauterine device and the implantable rod device. The success of these methods is demonstrable due to the "perfect use" and "typical use" failure rates being near identical. Pediatricians must be comfortable counseling patients, including adolescents, about LARC methods and how to access them. This primer provides some background about the types of LARC methods, details about their efficacy and side effects, and the role of the primary pediatrician. [Pediatr Ann. 2017;46(3):e79-e82.].
[Mh] Termos MeSH primário: Anticoncepcionais Femininos/administração & dosagem
Desogestrel/administração & dosagem
Dispositivos Intrauterinos
Gravidez na Adolescência/prevenção & controle
[Mh] Termos MeSH secundário: Adolescente
Aconselhamento Diretivo
Feminino
Seres Humanos
Pediatria
Gravidez
Atenção Primária à Saúde
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contraceptive Agents, Female); 304GTH6RNH (etonogestrel); 81K9V7M3A3 (Desogestrel)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171003
[Lr] Data última revisão:
171003
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170314
[St] Status:MEDLINE
[do] DOI:10.3928/19382359-20170220-03


  8 / 1378 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28257962
[Au] Autor:Brunson MR; Klein DA; Olsen CH; Weir LF; Roberts TA
[Ad] Endereço:Department of Pediatrics, San Antonio Military Medical Center, Fort Sam Houston, TX; Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD. Electronic address: michael.r.brunson.mil@mail.mil.
[Ti] Título:Postpartum contraception: initiation and effectiveness in a large universal healthcare system.
[So] Source:Am J Obstet Gynecol;217(1):55.e1-55.e9, 2017 Jul.
[Is] ISSN:1097-6868
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Repeat pregnancies after a short interpregnancy interval are common and are associated with negative maternal and infant health outcomes. Few studies have examined the relative effectiveness of postpartum contraceptive choices. OBJECTIVE: We aimed to determine the initiation trends and relative effectiveness of postpartum contraceptive methods, with typical use, on prevention of short delivery intervals (≤27 months) among women with access to universal healthcare, including coverage that entails no co-payments and allows unlimited contraceptive method switching. STUDY DESIGN: This retrospective cohort study included women who were enrolled in the United States military healthcare system who were admitted for childbirth between October 2010 and March 2015, with ≥6 months postpartum enrollment. With the use of insurance records, we determined the most effective contraceptive method initiated during the first 6 months after delivery, even if subsequently discontinued. Rates of interdelivery intervals of ≤27 months, as proxies for interpregnancy intervals ≤18 months, were determined with the use of the Kaplan-Meier estimator. Women who were disenrolled, who reached 27 months after delivery without another delivery, or who reached the end of the study period were censored. The influence of sociodemographic variables and contraceptive choices on time to subsequent delivery was evaluated by Cox regression analysis, which accounted for a possible correlation among multiple deliveries by an individual woman. RESULTS: During the study timeframe, 373,840 women experienced a total of 450,875 postpartum intervals. Women averaged 27 (standard deviation, 5.3) years of age at the time of delivery; 33.9% of them were <25 years old; 15.5% of them were active duty service members, and 31.6% of them had insurance sponsors of junior enlisted rank (which suggests lower income). Postpartum contraceptive methods that were initiated included self or partner sterilization (7%), intrauterine device (13.5%), etonogestrel implant (3.4%), depot medroxyprogesterone acetate (2.5%), and pill, patch, or ring (36.8%). Furthermore, 36.7% of them did not initiate a prescription method. Etonogestrel implant initiation increased from 1.7% of postpartum women in the first year of our study to 5.3% in the final year. The estimated short interdelivery interval rate was 17.4%, but rates varied with contraceptive method: 1% with sterilization, 6% with long-acting reversible contraception, 12% with depot medroxyprogesterone, 21% with pill, patch, or ring, and 23% with no prescription method. In a multivariable analysis, the adjusted hazard of a short interdelivery interval was highest among women who were younger, on active duty, or with officer insurance sponsors. Compared with nonuse of any prescription contraceptive, the use of an intrauterine device reduced the hazard of a subsequent delivery (adjusted hazard ratio, 0.19; 95% confidence interval, 0.18-0.20), as did etonogestrel implant (adjusted hazard ratio, 0.21; 95% confidence interval, 0.19-0.23); the pill, patch, or ring had less effect (adjusted hazard ratio, 0.80; 95% confidence interval, 0.78-0.81). CONCLUSION: Postpartum initiation of long-acting reversible contraception is highly effective at the prevention of short interdelivery intervals, whereas pill, patch, or ring methods are associated with rates of short interdelivery intervals similar to users of no prescription contraception. This study supports long-acting reversible contraception as first-line recommendations for postpartum women who wish to retain fertility but avoid early repeat pregnancy.
[Mh] Termos MeSH primário: Anticoncepção/métodos
Assistência à Saúde
Período Pós-Parto
[Mh] Termos MeSH secundário: Administração Cutânea
Adolescente
Adulto
Estudos de Coortes
Comportamento Contraceptivo
Anticoncepcionais Femininos/administração & dosagem
Anticoncepcionais Orais
Desogestrel/administração & dosagem
Implantes de Medicamento
Feminino
Seres Humanos
Dispositivos Intrauterinos
Acetato de Medroxiprogesterona
Militares
Gravidez
Estudos Retrospectivos
Esterilização Reprodutiva
Fatores de Tempo
Estados Unidos
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contraceptive Agents, Female); 0 (Contraceptives, Oral); 0 (Drug Implants); 304GTH6RNH (etonogestrel); 81K9V7M3A3 (Desogestrel); C2QI4IOI2G (Medroxyprogesterone Acetate)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170821
[Lr] Data última revisão:
170821
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170305
[St] Status:MEDLINE


  9 / 1378 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28256919
[Au] Autor:López-Picado A; Lapuente O; Lete I
[Ad] Endereço:a Araba Research Unit , Araba University Hospital , Vitoria , Spain.
[Ti] Título:Efficacy and side-effects profile of the ethinylestradiol and etonogestrel contraceptive vaginal ring: a systematic review and meta-analysis.
[So] Source:Eur J Contracept Reprod Health Care;22(2):131-146, 2017 Apr.
[Is] ISSN:1473-0782
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To assess the efficacy and tolerability (side-effects profile), and compliance of the combined contraceptive vaginal ring (CCVR) compared with combined oral hormonal contraceptives (COC). DATA SOURCES: The PubMed, Embase, POPLINE, Cochrane Central Register of Controlled Trials (CENTRAL), LILACS, ClinicalTrials.gov, Clinical Trials Registry Platform (ICTRP) and CINAHL databases were searched. METHODS OF STUDY SELECTION: Electronic databases were searched for randomised clinical trials comparing the CCVR with COC with a duration of at least 3 months between 01 December and 15 December 2015. The primary outcome was efficacy. The secondary outcomes were compliance, absence of withdrawal bleeding, breakthrough bleeding, nausea and headache. Heterogeneity was assessed using I statistic and Cochran's Q statistic. Results were expressed as odds ratios (OR) with 95% confidence intervals (CIs) using random-effects models or fixed-effects models depending on the heterogeneity. RESULTS: 4368 records were identified, 2844 of which were removed after duplicates and 1524 records were screened. Of these, 1503 were excluded and 21 full text articles were assessed for eligibility. After removing another 7 articles, 14 records were finally included in the qualitative and quantitative analysis. The results show a trend to higher efficacy for the CCVR in preventing pregnancy (Peto OR: 0.52 [95% CI: 0.26-1.04]) and a significantly lower presence of nausea (Peto OR: 0.66 [95% CI: 0.46-0.93]). More cycles were compliant in the CCVR group (Peto OR: 1.22 [95% CI: 1.12-1.32]) and fewer women reported breakthrough bleeding (Peto OR: 0.68 [95% CI: 0.51-0.91]). CONCLUSIONS: Our findings demonstrate that the CCVR is as effective and tolerable as the COC but with a better bleeding profile.
[Mh] Termos MeSH primário: Anticoncepcionais Femininos/administração & dosagem
Dispositivos Anticoncepcionais Femininos/efeitos adversos
Dispositivos Anticoncepcionais Femininos/estatística & dados numéricos
Desogestrel/efeitos adversos
Etinilestradiol/administração & dosagem
[Mh] Termos MeSH secundário: Anticoncepcionais Femininos/efeitos adversos
Desogestrel/administração & dosagem
Implantes de Medicamento/efeitos adversos
Etinilestradiol/efeitos adversos
Feminino
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Contraceptive Agents, Female); 0 (Drug Implants); 304GTH6RNH (etonogestrel); 423D2T571U (Ethinyl Estradiol); 81K9V7M3A3 (Desogestrel)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170304
[St] Status:MEDLINE
[do] DOI:10.1080/13625187.2017.1287351


  10 / 1378 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28219567
[Au] Autor:Thomas PA; Di Stefano D; Couteau C; D'Journo XB
[Ad] Endereço:Department of Thoracic Surgery, Hôpital Nord-APHM, Aix-Marseille University, Marseille, France. Electronic address: pathomas@ap-hm.fr.
[Ti] Título:Contraceptive Implant Embolism Into the Pulmonary Artery: Thoracoscopic Retrieval.
[So] Source:Ann Thorac Surg;103(3):e271-e272, 2017 Mar.
[Is] ISSN:1552-6259
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:An 18-year old woman had migration of a subdermal contraceptive implant in a subsegmental branch of her left lower lobe pulmonary artery. She was managed successfully through a conservative surgical approach, as the implant was removed from the pulmonary artery thoracoscopically, thereby avoiding the need of thoracotomy or lung resection.
[Mh] Termos MeSH primário: Anticoncepcionais Femininos/efeitos adversos
Desogestrel/efeitos adversos
Implantes de Medicamento/efeitos adversos
Embolia Pulmonar/etiologia
Toracoscopia/métodos
[Mh] Termos MeSH secundário: Adolescente
Feminino
Seres Humanos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contraceptive Agents, Female); 0 (Drug Implants); 304GTH6RNH (etonogestrel); 81K9V7M3A3 (Desogestrel)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170413
[Lr] Data última revisão:
170413
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170222
[St] Status:MEDLINE



página 1 de 138 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde